NCT02624557View on ClinicalTrials.gov

Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 21, 2015

Primary Completion Date

October 1, 2017

Study Completion Date

October 1, 2017

Conditions
Hepatic Impairment
Interventions
DRUG

Alpelisib

Subjects will receive a single dose of 300 mg alpelisib.

Trial Locations (4)

32809

Orlando Clinical Research Center, Orlando

33136

University of Miami / Clinical Research Services, Inc., Miami

55404

DaVita Clinical Research, Minneapolis

80228

DaVita Clinical Research-Denver, Lakewood

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY